GovChime
Notice ID: 00d139c6a6c949ae8dd069d36de28667Sources SoughtArchived

BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response

Archived on January 3, 2026. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
3:00 PM EST
Posted
November 7, 2025
Notice type
Sources Sought
Set-aside
No Set aside used
Agency
Department of Health and Human ServicesOFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE

Notice details

Office
BARDA - ASPR / DAAPPO / BARDA DCMA
Place of performance
Washington, District of Columbia, 20024
Last updated
Nov 6, 2026
First published
Last updated on SAM.gov

Identifiers

Notice ID
00d139c6a6c949ae8dd069d36de28667

Description

1.    Objective

The objective of this Sources Sought Notice (SSN) / Request for Information (RFI) is for BARDA program officials to better refine the requirements for vaccine medical countermeasures for pandemic influenza preparedness and response. BARDA is considering establishing long-term partnerships with multiple contractors. The information requested from this SSN/RFI will serve as continued market research while also assisting with requirements development of this vital program.  None of the information in this SSN/RFI is intended to suggest a particular approach or contract solution.

2.0       Project Scope

BARDA seeks Contractor(s) to support the continuation of the Vaccine MCMs for Pandemic Influenza Preparedness and Response Program.  Contractors will furnish all the necessary services, qualified personnel, materials, supplies, equipment and facilities (U.S. facilities preferred) not otherwise provided by the USG as needed to provide MCMs, such as vaccines, antigens, and adjuvants, for pandemic preparedness and response or as required in response to a public health emergency; produce antigen and vaccines against influenza virus or other viruses with pandemic potential as required by BARDA; produce antigens, adjuvants, and/or vaccines to support USG efforts to further improve influenza vaccines (for which feasibility data is available); and support rapid regulatory decisions and manufacturing readiness by generating and submitting to FDA all relevant data (e.g., analytical, nonclinical, clinical, and/or chemistry, manufacturing, and controls (CMC)), including data generated during interpandemic periods.

3.0       Sources Sought Notice (SSN)

BARDA is interested in advancing vaccine medical countermeasures for pandemic influenza preparedness and response. BARDA anticipates awards will be made to multiple contractors with the best solutions and capabilities to meet the following mandatory eligibility criteria:

     3.1.1 Mandatory Eligibility Criteria:

To be eligible for award, the Offeror must produce vaccines against influenza and influenza strains with pandemic potential; must demonstrate a successful experience in the manufacturing of influenza vaccine by:

  1. Holding a U.S. influenza vaccine license; or
  2. Have developed an influenza vaccine as evidenced by:
    1. Submission of a BLA for seasonal or pandemic influenza vaccine

Note: Failure to adequately document compliance of the above mandatory requirement will result in the elimination of the Offeror from further consideration. No further discussions will be held.

BARDA encourages qualified contractors to respond so we can better understand the current state of the science.

SSN Responders: Please submit  evidence of mandatory eligibility criteria, vendor’s capabilities statement, and a request to participate in the RFI by email to Laura.Saddison@hhs.gov no later than 3:00 pm EST Dec 19, 2025.

This SSN/RFI is issued for information and planning purposes only and does not constitute a solicitation. All information received in response to the SSN/RFI that is marked as proprietary will be handled accordingly by the Government. Responses to this SSN/RFI are not considered offers and cannot be accepted by BARDA to form a binding contract. Responders are solely responsible for all expenses associated with responding to this SSN/RFI. All information submitted in response to this SSN/RFI shall remain with the Government and will not be returned.

NOTE: *BARDA may compete RFP#75A50126R00001 amongst eligible respondents of this SSN/RFI only.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Primary Contact

Documents

No documents available.

Lifecycle

  1. 3
    Version 3Sources SoughtArchivedCurrent

    BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response

    Notice 00d139c6a6c949ae8dd069d36de28667 on SAM.gov

  2. 6
    Version 6PresolicitationArchived

    Type changed from Sources Sought to Presolicitation

    Presolicitation Notice - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response

    Notice 7f2d0909120749a39c61c64ff933f1a6 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
BARDA seeks Contractor(s) to support the continuation of the Vaccine Medical Counermeasures (MCM's) for Pandemic Influenza Preparedness and Response Program. Contractors will furnish all the necessary services, qualified personnel, materials, supplies, equipment and facilities (U.S. facilities preferred) not otherwise provided by the USG as needed to provide MCMs, such as vaccines, antigens, and adjuvants, for pandemic preparedness and response or as required in response to a public health emergency; produce antigen and vaccines against influenza virus or other viruses with pandemic potential as required by BARDA; produce antigens, adjuvants, and/or vaccines to support USG efforts to further improve influenza vaccines (for which feasibility data is available); and support rapid regulatory decisions and manufacturing readiness by generating and submitting to FDA all relevant data (e.g., analytical, nonclinical, clinical, and/or chemistry, manufacturing, and controls (CMC)), including data generated during interpandemic periods. Mandatory Qualification Requirements: To be eligible for award, the Offeror must produce vaccines against influenza and influenza strains with pandemic potential; must demonstrate a successful experience in the manufacturing of influenza vaccine by: 1. Holding a U.S. influenza vaccine license; or 2. Have developed an influenza vaccine as evidenced by: a. Submission of a Biologics License Application (BLA) for seasonal or pandemic influenza vaccine Please see full solicitation details and proposal submission instructions detailed in attachments 01-21 of this notice.
100%
Solicitation11/20/2026
This announcement serves as a reissuance of the BARDA DRIVe EZ-BAA, now known as EZ-BAA-22-100-SOL-00003. This announcement hereby supersedes and replaces prior iterations of the BARDA DRIVe EZ-BAA (e.g. BAA-20-100-SOL-0002). Please reference the attached announcement and applicable amendments for specifics. Additionally, please visit https://drive.hhs.gov/.
73%
Solicitation10/18/2027
This announcement serves as a reissuance of the BARDA DRIVe EZ-BAA, now known as EZ-BAA-22-100-SOL-00003. This announcement hereby supersedes and replaces prior iterations of the BARDA DRIVe EZ-BAA (e.g. BAA-20-100-SOL-0002). Please reference the attached announcement and applicable amendments for specifics. Additionally, please visit https://drive.hhs.gov/.
73%
Solicitation10/18/2027
This announcement serves as a reissuance of the BARDA DRIVe EZ-BAA, now known as EZ-BAA-22-100-SOL-00003. This announcement hereby supersedes and replaces prior iterations of the BARDA DRIVe EZ-BAA (e.g. BAA-20-100-SOL-0002). Please reference the attached announcement and applicable amendments for specifics. Additionally, please visit https://drive.hhs.gov/. _______ Amendment 001: This amendment to the EZBAA hereby opens the following research areas of interest ("AOI"). Please review the amendment for details of each AOI, including closing dates: AOI #15: ReDIRECT AOI #16: Lab at Home AOI #17: Digital MCMs AOI #18: Host-Directed Therapeutics AOI #19: Healing Lungs AOI #20: DRIVe Forward AOI #21: Vaccines on Demand AOI #22: ReBooT AOI #23: Host-Based Diagnostics _____
73%
Solicitation10/18/2027
This announcement serves as a reissuance of the BARDA DRIVe EZ-BAA, now known as EZ-BAA-22-100-SOL-00003. This announcement hereby supersedes and replaces prior iterations of the BARDA DRIVe EZ-BAA (e.g. BAA-20-100-SOL-0002). Please reference the attached announcement and applicable amendments for specifics. Additionally, please visit https://drive.hhs.gov/. _______ Amendment 001: This amendment to the EZBAA hereby opens the following research areas of interest ("AOI"). Please review the amendment for details of each AOI, including closing dates: AOI #15: ReDIRECT AOI #16: Lab at Home AOI #17: Digital MCMs AOI #18: Host-Directed Therapeutics AOI #19: Healing Lungs AOI #20: DRIVe Forward AOI #21: Vaccines on Demand AOI #22: ReBooT AOI #23: Host-Based Diagnostics _____ 11/8/22 - Please see Amendment 002 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Adding the the following Area of Interest (AOI): AOI #24: REPAIR 2. Clarifying an adminstrative error. _____ 11/14/22 - Please see Amendment 003 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Revising the following Area of Interest (AOI): AOI #19: Healing Lungs _____ 12/15/22 - Please see Amendment 004 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Updating the closing date for the following Area of Interest (AOI): AOI #21: Vaccines on Demand ______ 1/11/23 - Please see Amendment 005 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Pausing the following Area of Interest (AOI) by establishing a new closing date of February 15, 2023 at 12:00PM ET: AOI #15: ReDIRECT ______ 2/1/23 - Please see Amendment 006 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Updating the closing date for the following Area of Interest (AOI): AOI #19: Healing Lungs 2. Updating the closing date for the following Area of Interest (AOI): AOI #17: Digital MCMs 3. Updating the closing date for the following Area of Interest (AOI): AOI #16: Lab at Home 4. Revising the following Area of Interest (AOI): AOI #16: Lab at Home ______ 2/3/23 - Please see Amendment 007 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Updating the closing date for the following Area of Interest (AOI): AOI #24: REPAIR ______ 5/1/23 - Please see Amendment 008 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Adding the following Area of Interest (AOI): AOI #25: FASTx 2. Updating the language in Section III (F) of the Easy Broad Agency Announcement titled “Plus (+) Phase”. ______ 5/18/23 - Please see Amendment 009 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Reopening the following Area of Interest (AOI), which is reopened to support project Next Gen: AOI #21: Vaccines on Demand ______ 5/25/23 - Please see Amendment 010 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Revising the following Area of Interest (AOI): AOI #24: REPAIR 2. Updating the closing date for the following Area of Interest (AOI): AOI #24: REPAIR ______ 6/27/23 - Please see Amendment 011 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Closing the following Area of Interest (AOI): AOI #18: Host-Directed Therapeutics 2. Closing the following Area of Interest (AOI): AOI #23: Host-Based Diagnostics 3. Updating the closing date for the following Area of Interest (AOI): AOI #19: Healing Lungs ______ 9/13/23 - Please see Amendment 012 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Updating the closing date for the following Area of Interest (AOI): AOI #16: Lab at Home 2. Updating the closing date for the following Area of Interest (AOI): AOI #17: Digital MCMs 3. Updating the closing date for the following Area of Interest (AOI): AOI #19: Healing Lungs 4. Revising the following Area of Interest (AOI): AOI #16 Lab at Home 5. Adding the following Area of Interest (AOI): AOI #26: Agnostic Diagnostic _______ 9/14/23 - Please see Amendment 013 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Pausing the following Area of Interest (AOI): AOI #20: DRIVe Forward ________ 9/26/23 - Please see Amendment 014 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Pausing the following Area of Interest (AOI): AOI #21: Vaccines on Demand _________ 10/26/23 - Please see Amendment 015 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Updating the closing date for the following Area of Interest (AOI): AOI #22: ReBoot 2. Updating the closing date for the following Area of Interest (AOI): AOI #25: FASTx 3. Revising the following Area of Interest (AOI): AOI #22: ReBoot 4. Revising the following Area of Interest (AOI): AOI #25: FASTx ___________ 10/30/23 - Please see Amendment 016 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Pausing the following Area of Interest (AOI): AOI #24: REPAIR __________ 11/15/23 - Please see Amendment 017 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Reopening the following Area of Interest (AOI): AOI #20: DRIVe Forward 2. Revising the following Area of Interest (AOI): AOI #20: DRIVe Forward __________ 12/13/23 - Please see Amendment 018 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Updating the closing date for the following Area of Interest (AOI): AOI #16: Lab at Home 2. Revising the following Area of Interest (AOI): AOI #16: Lab at Home 3. Pausing the following Area of Interest (AOI): AOI #17: Digital MCMs 4. Updating the closing date for the following Area of Interest (AOI): AOI #19: Healing Lungs __________ 01/03/24 - Please see Amendment 019 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Reopening the following Area of Interest (AOI): AOI #15: ReDIRECT 2. Revising the following Area of Interest (AOI): AOI #15: ReDIRECT __________ 01/10/24 - Please see Amendment 020 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Pausing the following Area of Interest (AOI): AOI #26: Agnostic Diagnostic 2. Adding a topic to the following Area of Interest (AOI): AOI #20: DRIVe Forward 3. Updating the closing date for the following Area of Interest (AOI): AOI #20: DRIVe Forward _________ 01/18/24 - Please see Amendment 021 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Adding the following Area of Interest (AOI): AOI #27: Stopping Secondary Spread __________ 2/5/24 - Please see Amendment 022 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Pausing the following research Area of Interest (AOI): AOI #27: Stopping Secondary Spread 2. Revise topics for the following research Area of Interest (AOI): AOI #20: DRIVe Forward __________ 02/12/24 - Please see Amendment 023 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Reopening the following Area of Interest (AOI): AOI #26: Agnostic Diagnostic __________ 02/21/24 - Please see Amendment 024 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Updating the closing date for the following Area of Interest (AOI): AOI #22: ReBooT 2. Updating the closing date for the following Area of Interest (AOI): AOI #25: FASTx __________ 03/04/24 - Please see Amendment 025 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Reopening the following Area of Interest (AOI): AOI #24: RePAIR 2. Revising the following Area of Interest (AOI): AOI #24: RePAIR __________ 03/12/24 - Please see Amendment 026 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Updating the closing date for the following Area of Interest (AOI): AOI #16: Lab at Home 2. Updating the closing date for the following Area of Interest (AOI): AOI #19: Healing Lungs _________ 04/22/24 - Please see Amendment 027 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Reopening the following Area of Interest (AOI): AOI #20: DRIVe Forward 2. Removing two topic areas and adding one topic area to the following Area of Interest (AOI): AOI #20: DRIVe Forward _________ 05/01/24 - Please see Amendment 028 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Updating the closing date for the following Area of Interest (AOI): AOI #15: ReDIRECT 2. Updating the closing date for the following Area of Interest (AOI): AOI #26: Agnostic Diagnostic 3. Reopening the following Area of Interest (AOI): AOI #17: Digital MCMs 4. Revising the following Area of Interest (AOI): AOI #17: Digital MCMs __________ 05/09/24 - Please see Amendment 029 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Pausing the following Area of Interest (AOI): AOI #16: Lab at Home 2. Updating the closing date for the following Area of Interest (AOI): AOI #19: Healing Lungs 3. Revising the following Area of Interest (AOI): AOI #19: Healing Lungs 4. Updating the closing date for the following Area of Interest (AOI): AOI #24: RePAIR _________ 09/24/24 - Please see Amendment 030 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Adding the following Area of Interest (AOI): AOI #28: Influenza Vaccine Innovation 2. Pausing the following Area of Interest (AOI): AOI #26: Agnostic Diagnostic ___________ 09/30/24 - Please see Amendment 031 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Reopening the following Area of Interest (AOI): AOI #24: RePAIR ___________ 10/10/24 - Please see Amendment 032 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: Update the closing date for the following Area of Interest (AOI): AOI #19: Healing Lungs Pause the following Area of Interest (AOI) on 10/31/24: AOI #17: Digital MCMs ___________ 10/31/24 - Please see Amendment 033 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: Reopen the following Area of Interest (AOI) on 11/1/24: AOI #15: ReDIRECT 2. Remove language requiring a Rough Order of Magnitude (ROM) from the record 11/26/2024 - Please see Amendment 034 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1) Reopen the following Area of Interest (AOI): AOI #22: ReBooT 2) Revise the following Area of Interest (AOI): AOI #22: ReBooT 3) Pause the following Area of Interest (AOI): AOI#24: RePAIR ___________ 1/13/2025 - Please see Amendment 035 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1) Reopen the following Area of Interest (AOI) on 1/15/2025: AOI #16: Lab at Home 2) Open the following Area of Interest (AOI): AOI #29: Type to Treat ___________ 2/14/2025 - Please see Amendment 036 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: Updating the closing date for the following Area of Interest (AOI): AOI #19: Healing Lung __________ 4/22/2025 - Please see Amendment 037 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this amendment, BARDA is revising the following Areas of Interest (AOI) to close effective immediately: AOI #19: Healing Lungs AOI #22: ReBooT AOI #29: Type to Treat Additional details can be found in the corresponding Amendment 037.
72%
Solicitation10/18/2027

Additional Details

Solicitation Number

75A50126R00001_RFI_SSN_NPIVS-2027

Archive Date

Jan 3, 2026

Office Address

WASHINGTON, DC, 20515